About 3 results found for searched term "TrkB-IN-1" (0.229 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M42718 | TrkB-IN-1 | Trk |
| TrkB-IN-1 is a potent and orally active TrkB agonist and has favorable PK properties. | ||
| M2790 | K252a | PKC |
| SF 2370; Antibiotic K-252a | ||
| K252a is an inhibitor of the BDNF receptor TrkB. K-252a inhibits protein kinase with IC50 values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca2+/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively. K-252a is a potent inhibitor (IC50 of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene. | ||
| M9626 | Sitravatinib | VEGFR/PDGFR |
| MGCD516; MG516 | ||
| Sitravatinib (MGCD516) is an orally active receptor tyrosine kinase (RTK) inhibitor. Inhibition of Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, and TRKB at 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, respectively. 29 nM, 5 nM and 9 nM. Sitravatinib alone has a potent antitumor effect and enhances pD-1 blockade activity by promoting the antitumor immune microenvironment. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
